pembrolizumab,IMM60
merck,Portage
['lung', 'melanoma', 'portage']
portage biotech reports updated interim data for lead inkt engager, port-2, in a phase 1/2 trial for the treatment of advanced melanoma and metastatic non-small cell lung cancer at the 2023 american society for clinical oncology (asco) annual meeting -... 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2